

**From:** [Giordano, Erica](#)  
**To:** [Patel, Manisha \(manisha.patel@novartis.com\)](#)  
**Cc:** ["Riggins, Cindy"; narin.ahmed@novartis.com](#)  
**Subject:** BL 125646 CMC Information Request  
**Date:** Monday, August 07, 2017 8:19:52 PM  
**Attachments:** [image001.png](#)

---

Good evening,

Can you please clarify the number of total and failed product lots (due to manufacturing issues) from the Morris Plains Facility only (excluding lots from Germany) used for B2202?

Please respond directly to this e-mail and follow-up by submitting the information as an official amendment to the BLA.

*Thank you,*

**Erica Giordano**

*Regulatory Project Manager*

**Center for Biologics Evaluation and Research**

**Office of Tissues and Advanced Therapies**

**U.S. Food and Drug Administration**

Tel: 240-402-8298

[Erica.Giordano@fda.hhs.gov](mailto:Erica.Giordano@fda.hhs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."